Clinical Trial Update: Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial comparing meningococcal ACWY conjugate vaccine to polysaccharide vaccine in children aged 2-10 assessing safety and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Meningococcal ACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))
• Meningococcal polysaccharide vaccine

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-11-05